REBEL EM is licensed under a
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
Archive
Tag: Pulmonary Embolism
VTE Recurrence in Subsegmental PE: What’s the Risk?
Background: The overall mortality and case-fatality rate for pulmonary embolism (PE) are decreasing. Yet reporting is increasing, suggesting we are overdiagnosing PE. Furthermore, management with anticoagulation is not entirely benign and places a potential risk of bleeding upon the patient. ...
The INSPIRATION Trial: Intermediate Dose Anticoagulation in Critically Ill Patients with COVID-19
Background: COVID-19 infection increases the risk of thrombosis due to multiple factors.(Rico-Mesa, 2020). Over the last 2 years, researchers have published 12 RCTs investigating various anticoagulation strategies among patients diagnosed with COVID-19 in multiple clinical settings. To date, only a multiplatform ...
The Pragmatic Combination of YEARS Score and Age-Adjusted D-Dimer
Background: The optimal approach to risk stratifying patients for pulmonary embolism (PE) remains elusive. Multiple decision instruments are available with varying degrees of complexity and acceptance among emergency medicine clinicians (Wells, Geneva, PERC, YEARS, age-adjusted D-dimer). The 2018 ACEP clinical ...
The HEP-COVID Trial: Therapeutic Anticoagulation in Non-Critically Ill COVID-19 Patients
Background: Patients with COVID-19 are at increased risk from thromboembolic phenomena. Patient-specific factors such as comorbidities and immobility have been linked to thrombosis. Disease-specific factors such as virus-induced endothelial changes and cytokine storm may also be triggers. Furthermore, patients with elevated ...
Showing Slide 1 of 6